Value & Innovation Forum

The Value & Innovation Forum is a collaboration of the National Forum for Heart Disease & Stroke Prevention and Patient Advocate Foundation, both 501(c)(3) nonprofit organizations. Briefing topics are selected by the Value & Innovation Forum Steering Committee which includes representatives of the Alliance of Community Health Plans, Association of Black Cardiologists, Caregiver Action Network, and National Osteoporosis Foundation, in addition to the National Forum and Patient Advocate Foundation. Briefings are made possible by funding from Amgen in accordance with the National Forum’s Policy on Corporate and Foundation Support and Relationships. This policy ensures transparency and integrity in the National Forum’s dealings with sponsors.


Value & Innovation Forum Briefing: Biosimilars

Hear from experts providing patient, policy, and data insights.

MORE DETAILS TO FOLLOW!


Briefings Archive

What Are Z Codes and How Do They Impact Health Equity? - September 21, 2021

Webinar Recording | Webinar Summary


Speaker Bios

Alan Balch, PhD, Chief Executive Officer, Patient Advocate Foundation & National Patient Advocate Foundation

Julia Resnick, Senior Program Manager for Strategic Initiatives, American Hospital Association

Katlyn Sollenberger, Site Specialist, The Rinehart Clinic, Wheeler, OR


Resources

Proposed New Codes for SDOH Z Codes

2021 ICD-10-CM from CMS

Z Codes Infographic from CMS

Kaiser Permanente Infographic on Z Codes

American Hospital Association ICD-10-CM Coding for Social Determinants of Health

Telehealth: Patient Access & Equity - June 2, 2021

Webinar Recording | Webinar Summary


Speaker Bios

Shonta Chambers, MSW
Executive Vice President, Health Equity & Community Engagement
Principal Investigator, SelfMade Health Network
Patient Advocate Foundation

Barbara Hutchinson, MD PhD, FACC
President, Chesapeake Cardiac Care
Past President, Association of Black Cardiologists

Connie Hwang, MD, MPH
Chief Medical Officer, Director of Clinical Innovation
Alliance of Community Health Plans


Resources

Patient Advocate Foundation Telehealth Tip Sheet

ACHP Fact Sheet – The Promise of Telehealth (April 2021)

Regional Payers Outline Challenges, Successes of Telehealth Implementation (AJMC Feb 2021)

Nonprofit Health Plans Launch Telehealth-First Options to Increase Access and Affordability (NEJM Catalyst April 2021)

Innovations and Alternatives to Traditional Utilization Management - December 14, 2020

Webinar Recording | Webinar Summary


Traditional utilization management has become burdensome for physicians and patients.  This 1-hour briefing brings forward innovative real-world examples to navigate utilization management.

Speakers

Kate Berry, Senior Vice President of Clinical Innovation, America’s Health Plans
Jay Scott, Director, Managed Care, Minnesota Oncology
Robin T. Zon, MD, FACP, FASCO Chair, ASCO Pathways Task Force
President, Finance & Quality Chair, Michiana Hematology-Oncology, PC


Moderator

Alan Balch, PhD, CEO, Patient Advocate Foundation, National Patient Advocate Foundation


Resources

American Society of Clinical Oncology (ASCO) Policy Statement On the Impact of Utilization Management Policies for Cancer Drug Therapies

America’s Health Insurance Plans (AHIP) Fast Prior Authorization Technology Highway (Fast PATH)

Journal Article: Streamlining and Reimagining Prior Authorization Under Value-Based Contracts: A Call to Action From the Value in Healthcare Initiative’s Prior Authorization Learning Collaborative

Navigating Cancer

Uptake and Pricing of Biosimilars & the "Rebate Wall": A Value & Innovation Forum Multi-Perspective Briefing - June 2, 2020

Webinar Recording | Webinar Summary | Slides


Biosimilars continue to be a controversial subject long after Congress created a pathway for their approval. The Value & Innovation Forum prides itself on creating forums that present all sides of an issue as well as new and interesting angles beyond the hotly debated. This session provides an interesting discussion about the “rebate wall” controversy in biosimilars, a patient perspective, and where the FDA is headed next.

Speakers

John M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention

Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation

Christine Simmon, JD, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines

Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration

Chad Pettit, Executive Director, Global Value Access and Policy, Amgen

Madelaine Feldman, MD, Practicing Rheumatologist, Founding Member & Past President, Rheumatology Alliance of Louisiana

Agenda


WELCOME

John M. ClymerJohn M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention
Bio


MODERATOR

Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation
Bio


Panelists

Christine Simmon, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines
Bio


Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration
Bio


Chad Pettit, Executive Director, Global Value Access and Policy, Amgen
Bio


Madelaine Feldman, MD, Practicing Rheumatologist, President, Coalition of State Rheumatology Organizations
Bio


Articles

Formulary Construction in America: ‘Perfectly Legal’ and ‘Perfectly Wrong

Op-Ed: Debate Over Pharmacy Benefit Managers a Matter of Price vs. Cost

Washington Must Change the System That Encourages High Drug Prices


White Paper

Lessons for the United States on Europe’s Biosimilar Experience


Websites

FDA Biosimilars for access to educational materials and information about biosimilar and interchangeable products.

Drugs@FDA for information on all FDA approved drug products, including labeling and review information.

FDA Advisory Committees for drug advisory committee meetings and materials related to biosimilars

FDA Purple Book a database of Licensed Biological Products for information on biological products, including if products are biosimilar to a reference product.

Amgen Biosimilars